Luo Dongcheng, Liao Sina, Li Qian, Lin Youzhi, Wei Junbao, Li Yongqiang, Liao Xiaoli
Department of First Chemotherapy, Guangxi Medical University Cancer Hospital, Nanning, China.
Hepatobiliary Surgery Department, Guangxi Medical University Cancer Hospital, Nanning, China.
Front Oncol. 2022 Jul 1;12:862600. doi: 10.3389/fonc.2022.862600. eCollection 2022.
Titled the "most destructive of all cancers", pancreatic cancer is a malignant tumor with a very poor prognosis and has a poor response to systemic therapy. At present, several studies have shown that tegafur-gimeracil-oteracil potassium (hereinafter referred to as TS-1) is no less superior to gemcitabine in the treatment of advanced pancreatic cancer. In addition, a number of current clinical studies have shown that targeted therapy combined with chemotherapy reflects therapeutic advantages in pancreatic cancer. Moreover, and experiments have also demonstrated that anlotinib can curb the proliferation of pancreatic cancer cells and induce their apoptosis. Here, we report for the first time that a patient with locally advanced pancreatic cancer achieved good efficacy after switching to TS-1 chemotherapy combined with anlotinib targeted therapy. Previously, the disease of the patient still rapidly progressed without control following the first switch to abraxane combined with gemcitabine chemotherapy (AG regimen) due to the progression after chemo-radiotherapy. In this case, the patient achieved progression-free survival (PFS) of over 14 months the treatment with anlotinib targeted therapy combined with TS-1 chemotherapy and secondary radiotherapy (prior to secondary radiotherapy, the patient achieved a PFS of nearly 12 months the treatment with oral anlotinib combined with TS-1). Up to now, the progress of the disease is ceased. The oral administration of targeted therapy and chemotherapy are still in progress and the general condition of the patient is good. This suggests that patients with advanced pancreatic cancer may benefit from treatment with the anlotinib targeted therapy combined with TS-1 chemotherapy.
胰腺癌被称为“所有癌症中最具毁灭性的”，是一种预后极差的恶性肿瘤，对全身治疗反应不佳。目前，多项研究表明，替吉奥（以下简称TS-1）在晚期胰腺癌治疗中并不逊色于吉西他滨。此外，目前多项临床研究表明，靶向治疗联合化疗在胰腺癌治疗中体现出治疗优势。而且，实验也证实安罗替尼可抑制胰腺癌细胞增殖并诱导其凋亡。在此，我们首次报告1例局部晚期胰腺癌患者在换用TS-1化疗联合安罗替尼靶向治疗后取得了良好疗效。此前，该患者在放化疗后病情进展，首次换用白蛋白结合型紫杉醇联合吉西他滨化疗（AG方案）后病情仍迅速进展且未得到控制。在此病例中，该患者采用安罗替尼靶向治疗联合TS-1化疗及二次放疗后实现了超过14个月的无进展生存期（PFS）（在二次放疗前，该患者采用口服安罗替尼联合TS-1治疗实现了近12个月的PFS）。截至目前，病情进展已停止。靶向治疗和化疗的口服给药仍在进行中，患者一般状况良好。这表明晚期胰腺癌患者可能从安罗替尼靶向治疗联合TS-1化疗中获益。
